Weekly treatment with SAMiRNA targeting the androgen receptor ameliorates androgenetic alopecia – Scientific Reports (2022)

Independent Scientific Research on RNA-Based Approaches for Androgenetic Alopecia

A peer-reviewed research article published in Scientific Reports (Nature Portfolio, 2022) validated SAMiRNA-AR68 (CosmeRNA ARI)—a weekly RNA-based topical tonic delivering results comparable to daily finasteride, with zero side effects observed.

According to the published results from double-blind clinical trials, participants experienced significant hair count increases using just one weekly application, demonstrating both measurable effectiveness and an excellent safety profile.

This landmark Nature publication confirms RNA technology's breakthrough potential for thicker, fuller hair—offering a convenient alternative to daily treatments while expanding the frontiers of scalp science.

Source (external publication):
Weekly treatment with SAMiRNA targeting the androgen receptor ameliorates androgenetic alopecia – Scientific Reports (2022)

This content is provided for informational purposes only. The above text is an independent editorial summary and does not reproduce or substitute the original publication. It is not intended to diagnose, treat, cure or prevent any medical condition.